Previous
Next

Continuous Drug Release

Discover advanced ADHD drug delivery with Quillivant XR (methylphenidate HCl)

Continuous release icon
Continuous release1,2
Consistent icon
Consistent1,2
Predictable icon
Predictable2

How the Technology Works

  • Our formulation of methylphenidate contains millions of drug-particle complexes1
  • Extended-release particles have coatings of various thicknesses that protect the medication and releases it consistently over time1
  • This protective layer makes sure the release of medication won’t be affected by food your child eats or differences in your child’s metabolism

See how our technology works and learn more about the smooth consistent drug release that makes Quillivant XR different

  • Study Results
  • Pharmacokinetics (PK) describes the way in which a person’s body absorbs, distributes, metabolizes, and excretes a medication. The PK properties of Quillivant XR were studied in healthy adults who were given 60 mg of Quillivant XR compared to an immediate-release (IR) liquid methylphenidate solution, in two equal doses of 30 mg each, 6 hours apart. Blood samples were collected before and then at several time points after taking the drug. The amount of methylphenidate in each sample was then measured in a laboratory.
  • As shown in the chart below, blood levels of methylphenidate increased rapidly after taking Quillivant XR, reaching a peak around 5 hours. Levels then gradually decreased from 5 hours through 24 hours.
    • Blood levels of methylphenidate in people who took the IR solution increased and decreased quickly. After a second dose of the IR solution, the blood levels again showed a quick rise and a quick drop off.

    • Unlike IR methylphenidate solutions, Quillivant XR provides steady levels throughout the day in a once-daily dose with no additional peaks.

Mean d-methylphenidate plasma concentration-time profiles3,4

Quillivant XR Mean d-Methylphenidate Plasma Concentration-Time Profiles Chart

IR = Immediate-Release
ER = Extended-Release

See more about Quillivant XR's results in treating ADHD symptoms.

Did you know...?

Dosing for Quillivant XR can be adjusted in small amounts as prescribed by your doctor and directed by your pharmacist.
Quillivant XR Liquid Dosing Plunger

Pay as little as $25 for your Quillivant XR prescription!*

ADHD Patient Reading Book with Friends #2

* Co-pay offer is subject to eligibility. Terms and Conditions apply.

References: 1. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 20. 2. Wigal SB, Childress AC, Belden HW, Berry SA. NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013;23(1):3-10. 3. Childress AC, Berry SA. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension. Postgrad Med. 2010 Sep;122(5):35-41. doi: 10.3810/pgm.2010.09.2199. PMID: 20861586 4. Quillivant XR [package insert]. Tris Pharma, Inc., Monmouth Junction, NJ.

Important Safety Information

Quillivant® XR (methylphenidate HCI) is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Quillivant XR has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep Quillivant XR in a safe place to prevent abuse and misuse. Never give your Quillivant XR to anyone else, because it may cause death or harm them. Selling or giving away Quillivant XR may harm others and is against the law.

See Additional Important Safety Information.
To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at (732) 940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Important Safety Information

Quillivant® XR (methylphenidate HCI) is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs. Quillivant XR has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Keep Quillivant XR in a safe place to prevent abuse and misuse. Never give your Quillivant XR to anyone else, because it may cause death or harm them. Selling or giving away Quillivant XR may harm others and is against the law.

Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with Quillivant XR and will monitor you or your child during treatment. Tell your physician if you, your child, or any family members have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Quillivant XR should not be taken if you or your child are allergic to methylphenidate hydrochloride, or any of the ingredients in Quillivant XR, or are taking or have taken within the past 14 days an antidepression medicine called a monoamine oxidase inhibitor or MAOI.

The following have been reported with the use of methylphenidate hydrochloride and other stimulant medicines:

  • Risks for people with serious heart disease: Sudden death has happened in people who have heart defects or other serious heart disease. Before starting Quillivant XR, tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.
    Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Quillivant XR.
  • Increase in blood pressure and heart rate.
    Your healthcare provider should check your or your child’s blood pressure and heart rate regularly during treatment with Quillivant XR.
  • Mental (psychiatric) problems, including new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms. Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression. Call the doctor right away if there are any new or worsening mental symptoms during treatment.

Quillivant XR may not be right for you or your child. Before starting Quillivant XR tell your or your child’s health care provider about all health conditions (or a family history of) including:

  • heart problems, heart disease, heart defects, or high blood pressure
  • mental problems including psychosis, mania, bipolar illness, or depression
  • circulation problems in fingers and toes
  • have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)
  • have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome
  • if you are pregnant or plan to become pregnant. It is not known if Quillivant XR will harm the unborn baby. There is a pregnancy registry for females who are exposed to Quillivant XR during pregnancy. The purpose of the registry is to collect information about the health of females exposed to Quillivant XR and their baby. If you or your child becomes pregnant during treatment with Quillivant XR, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388 or https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.
  • if you are breastfeeding or plan to breast feed. Quillivant XR passes into your breast milk. You and your healthcare provider should decide if you will take Quillivant XR or breastfeed.
  • Do not start any new medicine while taking Quillivant XR without talking to your healthcare provider first.

What should I avoid while taking Quillivant XR?

Quillivant XR should not be taken with MAOI medicines or if you stopped taking an MAOI in the last 14 days. Do not drink alcohol while taking Quillivant XR. This may cause a faster release of your methylphenidate dose.

Quillivant XR may cause serious side eff­ects, including:

  • See “What is the most important information I should know about Quillivant XR?” for information on reported heart and mental problems

Other serious side eff­ects include:

  • Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes.
    Call the doctor right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with Quillivant XR.
  • New or worsening tics or worsening Tourette’s syndrome. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with Quillivant XR.
  • Painful and prolonged erections (priapism) have occurred with methylphenidate. If you or your child develop priapism seek medical help right away. Because priapism can cause long lasting damage, it should be checked by a health care provider right away.
  • Slowing of growth (height and weight) in children. Children should have their height and weight checked often during treatment with Quillivant XR. Quillivant XR treatment may be stopped if your child is not gaining weight or height.
  • Eye problems (increased pressure in the eye and glaucoma). Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.

Most Common side eff­ects include:

  • Decreased appetite
  • Trouble sleeping
  • Nausea
  • Vomiting
  • Indigestion
  • Stomach pain
  • Weight loss
  • Anxiety
  • Dizziness
  • Irritability
  • Mood swings
  • Fast heart beat
  • Increased blood pressure

These are not all the possible side effects of Quillivant XR.

To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at (732) 940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is Quillivant XR?

Quillivant XR is a central nervous system stimulant prescription medicines. Quillivant XR is a chewable tablet.

Quillivant XR is used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Quillivant XR may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.

It is not known if Quillivant XR is safe and effective in children under 6 years of age.

Please see Full Prescribing Information for Quillivant XR, including Boxed Warning about Abuse, Misuse and Addiction, and Medication Guide.

up arrowTop